S ystemic lupus erythematosus (SLE) is a multisystemic chronic autoimmune inflammatory disorder that is associated with a high risk for the development of renal and cardiovascular diseases, 1,2 which are major causes of mortality in these patients. 3 It predominantly affects young women of child-bearing age, the same population that is at lowest relative risk of atherosclerotic heart disease. In fact, women with lupus (aged 35-44 years) are >50× as likely as healthy women without lupus to have a myocardial infarction.
leading to increased production of autoantibodies and progressive lupus-like autoimmune disease. 10 Furthermore, PPARβ/δ signaling can intrinsically regulate T-helper (Th) biology by altering proliferative capacity and expression of interferon-γ (IFN-γ) and regulating Th17 differentiation. 11 However, whether PPARβ/δ activation would reduce the production of autoantibodies and protect against SLE progression is unknown. Moreover, it has been proposed that immune dysregulation in SLE may be responsible for the higher incidence of insulin resistance and metabolic syndrome observed in these patients, which may also contribute to vascular dysfunction. 12 In previous studies, it has been reported that PPARβ/δ activation reduces blood pressure, improves metabolic profile and vascular function, [13] [14] [15] [16] [17] [18] and has anti-inflammatory and renal protective effects. 19 In addition, preclinical evidences suggest that PPARβ/δ activators may prevent and treat obesity-induced insulin resistance and type 2 diabetes mellitus, whereas clinical trials have highlighted their potential use in dyslipidemia. 20 Given that SLE is a chronic inflammatory disorder with prominent hypertension, insulin resistance, inflammation, and renal disease, PPARβ/δ activation could be an attractive therapeutic option. Therefore, in this study, we propose that the treatment with a PPARβ/δ agonist can ameliorate SLE-associated hypertension and renal injury. With this aim, we have analyzed the effects of chronic treatment with the highly selective PPARβ/δ agonist GW0742 21 in a mouse model (NZBWF1 mice) that closely mimics human SLE. Like in humans with SLE, the NZBWF1 mice produce anti-dsDNA antibodies, develop immune complex glomerulonephritis, and, more importantly, they develop hypertension. [22] [23] [24] Finally, and similarly to humans, the cause of SLE in this model is thought to be polygenic, and female NZBWF1 mice are more prominently affected than males.
Methods

Animals and Experimental Groups
The investigation conforms to the National Institutes of Health Guide for the Care and Use of Laboratory Animals and by the Ethic Committee of Laboratory Animals of the University of Granada (Spain; Ref. 459-bis-CEEA-2012). Thirty-week-old female NZBWF1 (SLE) and NZW/LacJ (control) mice obtained from Jackson Laboratories (Bar Harbor, ME) were randomly assigned to receive by oral gavage GW0742 (5 mg kg
) or with the PPARβ/δ antagonist GSK0660 1 mg kg −1 d −1 intraperitoneally plus GW0742 orally for 5 weeks. GSK0660 was diluted first in dimethyl sulfoxide and later in NaCl 0.9% (dimethyl sulfoxide <1%). Mice were treated with the corresponding oral and intraperitoneally vehicles of the substances given to the other groups. Urine was collected and assessed for the presence of proteinuria, as described previously. 24 Animals were maintained at a constant temperature (24±1°C), with a 12-hour light/dark cycle, on a standard chow and water ad libitum. Mice were randomly divided into 5 groups: control untreated (Ctrl), control treated with GW0742 (GW), SLE untreated (SLE), SLE treated with GW0742 (SLE+GW), and SLE treated with GW0742 and GSK0660 (SLE+GW+GSK).
Parameters Determined
Systolic blood pressure (SBP) evolution was measured by tail-cuff plethysmography and final mean arterial blood pressure and heart rate by intra-arterial register. 24 At the end of the experiment, plasmatic concentrations of anti-dsDNA antibodies, cytokines, glucose, triglycerides, high-density lipoprotein (HDL), and total cholesterol were measured, as previously described. 22 In addition, physical characteristics, cardiac, and renal weight indices were also measured.
Renal injury was assessed by proteinuria determination 25 and histopathologic evaluation of kidneys, which was performed in sections stained with hematoxylin-eosin, Periodic acid-Schiff, and Masson trichrome. 24 Descending thoracic aortic rings were mounted in a wire myograph for isometric tension measurement as previously described. 24 Vascular reactive oxygen species (ROS) levels were estimated from the ratio of ethidium/4,6-diamidino-2-phenylindole dichlorohydrate fluorescence in sections of unfixed thoracic aortic rings incubated with dihydroethidium and counterstained with the nuclear stain 4,6-diamidino-2-phenylindole dichlorohydrate. 24 Vascular nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity was measured by the lucigenin-enhanced chemiluminescence assay. Protein and mRNA expression were measured by Western blotting analysis and reverse transcriptase-polymerase chain reaction analysis, respectively, as previously described. 13 The sequences of the sense and antisense primers used for amplification are described in Table S1 in the online-only Data Supplement.
Statistical Analysis
Results are expressed as means±SEM. Statistical analyses were performed using Graph Pad Prism 5 software (Methods in the in the online-only Data Supplement).
Results
Effects of GW0742 on Blood Pressure, Cardiac and Renal Hypertrophy, Spleen Lymphocytes, and Plasma Determinations
The time course of tail SBP is shown in Figure 1A and the final mean arterial blood pressure and heart rate measured by direct recordings in Figure 1B . Initial SBP was significantly higher in SLE mice when compared with controls. No significant changes in SBP were induced after 5 weeks of vehicle treatment either in SLE or in control mice. GW0742 treatment reduced BP in SLE mice ( Figure 1A and 1B), without significantly affecting heart rate ( Figure 1B ). This effect was prevented by coadministration of the PPARβ/δ antagonist GSK0660, confirming that PPARβ/δ activation was responsible for the effects of GW0742. There is a significant increase in body weight in SLE mice compared with control animals which was unaffected by GW0742 treatment (Table S2) . Heart weight/tibia length, left ventricular weight/tibia length, and kidney weight/tibia length indices were higher in SLE (Table  S2 ) than in control mice. GW0742 treatment reduced significantly both cardiac and renal hypertrophy found in SLE mice, which was inhibited by PPARβ/δ blockade with GSK0660.
SLE disease activity, measured by plasma levels of antidsDNA autoantibodies, was significantly greater in SLE mice compared with control mice, as previously reported (Figure 2A) . 24, 26 GW0742 treatment significantly reduced the levels of anti-dsDNA in SLE, being without effect in control mice. Disease progression has been associated with splenomegaly, most probably because of a lymphoproliferative disorder. 27 We also found splenomegaly in lupus mice, which was appreciably reduced by PPARβ/δ activation with GW0742 ( Figure 2B ).
Increased production of autoantibodies and progressive lupus-like autoimmune disease are associated with a delay in the clearance of apoptotic cells. 10 Opsonins, proteins secreted by macrophages, such as C1q, thrombospondin-1, and milk fat globule-epidermal growth factor-8, enhance the recognition and phagocytosis of apoptotic cells by macrophages. 28 Kupffer cells are liver resident macrophages, considered the primary source of opsonins that circulate in the serum, 29 and this prompted us to investigate the opsonin expression in the livers of mice from all experimental groups. We found that in vivo pharmacological activation of PPARβ/δ enhances hepatic opsonins (C1qa, C1qb, thrombospondin-1, and milk fat globule-epidermal growth factor-8) gene expression only in lupus mice, which tended to be reduced in these animals when compared with control ( Figure 2C ). In the liver, the mRNA levels of PPARα ( Figure S1A ) were reduced in SLE mice when compared with control, whereas PPARγ ( Figure  S1B ) and PPARβ/δ ( Figure S1C ) were similar. GW0742 did not modify hepatic mRNA levels of PPARα and PPARγ, but increased PPARβ/δ expression. In addition, increased mRNA levels of proinflammatory cytokines (tumor necrosis factor-α [TNF-α], interleukin-1β [IL-1β], and IL-6) and reduced levels of adiponectin were also found in liver from SLE mice. In vivo PPARβ/δ activation restored the hepatic levels of these cytokines to those found in control mice ( Figure S1D ). Fasting plasma glucose and total cholesterol levels were higher in SLE mice when compared with control (Table S2) , with similar levels of triglycerides and HDL. GW0742 reduced the levels of glucose and increased HDL in a PPARβ/δ-dependent manner.
To determine the immunomodulatory actions of PPARβ/δ activation, we measured the levels of B and T cells in spleens from all experimental groups ( Figure 3A ). The number of total cells ( Figure 3A ) and the percentages of T ( Figure 3B ), and B ( Figure 3C ) cells were higher in spleens from SLE mice than in control group. In addition, the percentages of Treg, Th1 ( Figure 3D ), and CD4 − IL17A + ( Figure 3E ) cells were also increased in splenocytes from SLE mice. GW0742 treatment significantly decreased the cell counts that were augmented in SLE mice. Plasma levels of IFN-γ, IL-21, TNF-α, IL-10, and IL-17 were also increased in SLE mice when compared with control, whereas plasma adiponectin levels were reduced. Again, PPARβ/δ activation normalized the levels of these parameters ( Figure S2 ).
Effects of GW0742 on Renal Injury
The comparative study of renal injury in different mice groups is shown in representative micrographs in Figure 4A and Table  S3 . No renal lesions were observed in control groups. At 35 weeks, extracapillary proliferation (crescent) in moderate intensity, segmental sclerosis, and abundant immune deposits on basal membrane of tuft capillary were detected in SLE mice group glomeruli with Masson trichrome stain. Tubular dilatation with hyaline casts and patch of chronic inflammatory infiltrate were present in <80% of SLE group kidneys. The treatment of SLE mice with GW0742 resulted in a significant reduction of tubular cast and immune deposits in tuft capillary; although the percentage of glomerulosclerosis and mesangial proliferation tended to be lower, no statistical differences were obtained in comparison with SLE group. In the group treated with GW0742 plus the PPARβ/δ antagonist GSK0660, the glomerular lesions were similar to SLE group. The number of nuclei per glomerular cross-section, which is a measure of glomerular cellularity and proliferation, was significantly increased in SLE mice when compared with control group. Also, the administration of GW0742 to SLE mice decreased the glomerular proliferation in comparison with SLE group, being this effect reversed by the antagonist GSK0660, which increased the number of cells of proliferative glomeruli to similar values obtained in SLE group.
Urinary albumin excretion was increased in SLE mice compared with controls and significantly reduced after GW0742 treatment, being this effect abolished by the coadministration of GSK0660 ( Figure 4B ).
The gene expression of the proinflammatory cytokines, TNF-α, IL-1β, and IL-6, in the renal cortical was increased in SLE mice when compared with control. PPARβ/δ activation significantly reduced these mRNA levels of these genes, being this effect also counteracted when the antagonist GSK0660 was concurrently administered to SLE mice ( Figure 4C ).
The mRNA levels of PPARα and PPARγ in renal cortex were significantly lower in SLE mice compared with control mice, whereas PPARβ/δ expression was similar in both groups. Treatment with GW0742 did not affect renal cortical PPARα and PPARγ expression in either control or SLE mice, but increased PPARβ/δ mRNA levels ( Figure S3 ). In addition, GW0742 increased mRNA level of PPARβ/δ target genes, carnitine palmitoyltransferase-1, UCP2 (uncoupling protein-2), and pyruvate dehydrogenase kinase-4. This increase was abolished by blocking PPARβ/δ with GSK0660, involving PPARβ/δ activation. 
Effects of GW0742 on Endothelial Function
Aorta from SLE mice showed strongly reduced endotheliumdependent vasodilator responses to acetylcholine. The treatment of SLE mice with GW0742 showed an increase in the acetylcholine-induced vasodilation when compared with vehicle-treated SLE mice ( Figure 5A ). These relaxant responses were suppressed by incubation for 30 minutes with the nitric oxide synthase (NOS) inhibitor N ω -nitro-l-arginine methyl ester (L-NAME) in all experimental groups ( Figure 5B ), suggesting a higher NO formation in vessels from control mice compared with those from SLE mice. No differences were observed among all experimental groups in the endothelium-independent relaxant response to sodium nitroprusside ( Figure 5C ).
Aortic endothelial NOS (eNOS) mRNA levels ( Figure 5D ) and protein expression ( Figure 5E ) were similar among all experimental groups. However, eNOS phosphorylation at Ser-1177 was significant reduced in SLE mice when compared with control. PPARβ/δ activation restored Ser-1177-eNOS phosphorylation at values similar to control ( Figure 5E ).
The mRNA levels of PPARβ/δ were significantly lower in aorta from SLE mice compared with control mice, whereas the expression of their target genes UCP2, carnitine palmitoyltransferase-1, and pyruvate dehydrogenase kinase-4 was similar in both groups. Treatment with GW0742 increased the mRNA levels of both PPARβ/δ and their target genes. These changes induced by GW0742 were inhibited by PPARβ/δ blockade with GSK0660, showing that the effects of GW0742 involved PPARβ/δ activation in the aorta ( Figure S4 ).
Effects of GW0742 on Vascular ROS Levels and NADPH Oxidase Activity
Aortic rings from SLE group showed marked increased aortic staining when compared with control group, which was significantly reduced by GW0742 treatment ( Figure 6A ). In addition, NADPH oxidase activity was increased in aortic rings from SLE mice when compared with control mice ( Figure  6B ), which were associated with significant mRNA increase of NADPH oxidase subunits ( Figure S5 ) NADPH oxidase 1 (NOX1), NOX2, p22 phox (phagocytic oxidase [phox]), and p47 phox . Chronic in vivo PPARβ/δ activation by GW0742 reduced significantly both the upregulation of NADPH oxidase subunits and the increased NADPH oxidase activity in SLE mice, but not in control mice.
To evaluate the role of NADPH oxidase-driven ROS production in endothelial function, we tested endothelium-dependent relaxation to acetylcholine in the presence of NADPH oxidase inhibitor apocynin. No significant differences among groups were observed after incubation with apocynin, showing the critical role of increased NADPH oxidase in the endothelial dysfunction found in aorta from SLE mice ( Figure 6C ).
Discussion
In this study, we investigated whether the PPARβ/δ agonist therapy reduces cardiovascular complications in an experimental model of this autoimmune disease accompanying with hypertension, the NZBWF1 mice, which similar features to human SLE. This study revealed that, in SLE mice, chronic PPARβ/δ activation with GW0742 treatment (1) markedly attenuated lupus disease progression as evidenced by reduced splenomegaly, B cells accumulation, and lower antidsDNA autoantibody activity, (2) significantly reduced the elevated SBP, (3) ameliorated heart and kidney hypertrophy, (4) improved renal morphological lesions, renal inflammation, and albuminuria, (5) restored endothelial function in SLE, and (6) exerted vascular protective effects that seem to be related to decreased ROS production as a result of NADPH oxidase subunit downregulation and increased NO bioavailability.
SLE is characterized by the production of autoantibodies, being the presence of anti-dsDNA antibodies, the hallmark in SLE. Kidney is one of the most frequently involved organs in SLE; deposition of autoantibodies in the kidneys triggers inflammation resulting in lupus nephritis, which may progress to end-stage renal failure. 30 In fact, transgenic overexpression of anti-dsDNA autoantibody in mice induced proteinuria and increased the sensitivity of Toll-like receptor 4 activation to induce severe SLE syndrome. 31 In the experimental model of SLE used in this study, the NZBWF1 mice, we also found increased anti-dsDNA activity. This correlated with albuminuria, inflammation, and morphological alterations in renal cortex, including immune complexes deposition, which were ameliorated after chronic GW0742 treatment, in association with reduced plasma anti-dsDNA titter. All these features in this genetic model of SLE are in agreement with previous data, 10 showing that genetic deficiency of PPARβ/δ increased both autoantibodies in sera and deposits of immune complexes in the glomeruli of pristane 32 (agent which induced lupus-like autoimmune disease by activating B cells)-injected mice. Interestingly, renal damage in SLE mice was associated with increased expression of inflammatory cytokines in kidney that was almost abolished by GW0742, despite only a partial reduction in plasma autoantibodies and immune complex deposition was obtained with the agonist treatment. These data suggested that GW0742 activated PPARβ/δ in the kidney, as denoted by increased PPARβ/δ expression, thus inhibiting the inflammatory cascade, as previously described in diabetic rats. 33 Although the increase in BP does not seem to be dependent on glomerulonephritis in individuals with SLE, 34-36 the protection from developing hypertension afforded by preventing autoimmunity is dependent on reductions in renal inflammation. In fact, blockade of TNF-α biological activity with etanercept attenuates the hypertension in this model. 23 Thus, the suppression of the increased renal cortex TNF-α mRNA levels induced by GW0742 treatment in SLE mice might be involved in its antihypertensive effects.
The defects in the clearance of apoptotic cells by macrophages lead to increased production of autoantibodies and promote the progression of SLE. In fact, an impaired ability of resident peritoneal macrophages from NZBWF1 female mice to engulf apoptotic cells have been demonstrated, 37 which might be related to the reduced expression of opsonins, proteins that facilitate the recognition and uptake of apoptotic cells by macrophages, as it has been detected in our experiment in the liver from lupus mice. In fact, the activation of PPARβ/δ increased the expression of hepatic opsonins only in SLE mice, in association with reduced plasma anti-dsDNA activity. In addition, humoral immune system activation plays a central role in the pathogenesis of SLE because there is evidence that B cells, which differentiate into antibody-producing plasma cells, are increased during SLE. 38 Furthermore, IL-21 drives B cells maturation and autoantibody production in rodent models of lupus. 39 Accordingly, we found a higher number of spleen B cells and increased plasma levels of IL-21 in SLE mice than in the control group, which were counteracted after GW0742 treatment in SLE mice, thus contributing to attenuate antibody activity in these treated mice. Moreover, despite their elevated proportion in aged lupus mice, Treg cells are ultimately unable to control cumulative impact of multiple genetic elements driving lymphocyte activation and autoreactivity. 40 The reduction induced by GW0742 in Treg cell counts might also reduce these processes, leading to a decrease of autoantibodies. However, it has been reported that B-cell depletion with anti-CD20 antibody, starting at 30 weeks of age in NZBWF1 female mice, once the inflammatory process has begun and antibodies are being produced, did not affect blood pressure. 8 Remarkably, in our experiment, pharmacological PPARβ/δ activation, which started at 30 weeks of age, reduced the levels of autoantibodies and attenuated hypertension, thus providing data that the improvement of the autoimmunity in SLE may be an important factor underlying in the control of hypertension, although other mechanisms induced by the PPARβ/δ agonist could be also involved.
Hypertension is often associated with impaired endothelial function, but whether this is causative in the progression of hypertension is difficult to prove. Numerous studies suggest that the endothelium is prominently affected during SLE, as demonstrated by the high risk for the development of atherosclerosis. 41, 42 Endothelial cell dysfunction represents the earliest indication of the development of cardiovascular disease and is also a principal element of SLE. 43 In NZBWF1 mice, we observed an impaired aortic endothelium-dependent relaxation response to acetylcholine. Interestingly, Ryan et al 44 found that the impaired response to acetylcholine begins before the development of proteinuria and results in increased blood pressure, suggesting that early changes in vessel function may contribute to the development of hypertension during SLE. Our present results extend previous findings of our group linking endothelial dysfunction and hypertension in SLE 24 because PPARβ/δ activation increased acetylcholine relaxation and reduced BP. Moreover, hypertensive SLE mice develop cardiac and renal hypertrophy when compared with control mice. Pharmacological PPARβ/δ activation in SLE mice was accompanied by significant amelioration in these structural alterations.
Inflammatory responses in the endothelium induced by circulating autoantibodies and other inflammatory mediators are known to contribute to the pathogenesis of endothelial dysfunction, and numerous studies have implicated the release of cytokines in the progression of SLE. 45 Therefore, we found increased plasma levels of proinflammatory cytokines TNF-α, IFN-γ, IL-17, and IL-21 in SLE, which correlate with changes in cell populations in the spleen. As it has been previously reported, 46 GW0742 reduced Th1 cells, as well as IFN-γ and IL-21 levels in plasma, thus reducing their deleterious effects in the vasculature. However, the molecular mechanisms involved in endothelial dysfunction in SLE mice have been never analyzed in detail. It is well known that NO secretion is required for normal endothelium-dependent vasodilatation, and SLE patients display a defect of eNOS function in endothelial cells. 47 We found that endothelium-dependent relaxations induced by acetylcholine were abolished by eNOS inhibition with L-NAME, suggesting a defect in NO pathway in SLE mice. However, no significant changes in eNOS expression were detected in SLE mice, whereas reduced eNOS phosphorylation at the activation site Ser-1177 indicates reduced NO production. Interestingly, the improvement in acetylcholine relaxation induced by GW0742 in SLE was suppressed by L-NAME, suggesting that GW0742 improved the eNOS pathway in aortic tissue, which was associated with the restoration of Ser-1177-eNOS phosphorylation by PPARβ/δ activation. In addition, the protective effects seem to be unrelated to changes in the sensitivity to the NO-cGMP pathway because the vasodilator response to the NO donor, nitroprusside, was unaffected by GW0742 treatment.
A key mechanism of endothelial dysfunction involves the vascular production of ROS, particularly O 2 − , which reacts rapidly with and inactivates NO. 48 We found that ROS levels are increased in aorta from SLE and that GW0742 reduced ROS content. The activity of the NADPH oxidase, considered the major source of O 2 − in the vascular wall, was markedly increased in SLE mice, accompanied with an increase in mRNA level of the subunits NOX1, NOX2, p22 phox , and p47 phox . NADPH oxidase-driven ROS production is a key event in endothelial dysfunction in SLE because incubation with the NADPH oxidase inhibitor apocynin increased the aortic endothelium-dependent relaxation to acetylcholine in SLE to similar level that found in control. GW0742 treatment inhibited the upregulation of these NADPH oxidase subunits and its activity in SLE mice. The normalization of ROS also seems to contribute to the restoration of endothelial function. Overall, these beneficial effects of GW0742 on endothelial function might be the results of the reduction in plasma cytokines and direct effects on the vasculature increasing eNOS phosphorylation 49 and reducing NADPH oxidase expression. [13] [14] [15] [16] [17] [18] Metabolic factors, such as hyperglycemia, insulin resistance, hypertriglyceridemia, and low HDL, can impair endothelial function. 50 In fact, the metabolic syndrome is highly prevalent in patients with SLE, 51 and it has been associated with increased cardiovascular risk. In these patients, metabolic syndrome may contribute to the development of atherosclerosis by increasing inflammation levels, arterial stiffness and decreasing circulating endothelial progenitor cells. 52 PPARβ/δ activation reduced hyperglycemia and increased HDL in SLE mice. We also showed that hepatic mRNA levels of proinflammatory cytokines, such as TNF-α, IL-1β, and IL-6, were higher in SLE mice compared with control mice. Hepatic PPARβ/δ activation reduced these markers of liver inflammation and consequently improved glucose metabolism. Moreover, it has been reported that GW0742 was also able to restore the hepatic production and plasma levels of adiponectin, an insulin-sensitizing adipokine, with potent protective effects against endothelial dysfunction 53 and autoantibodies production. 54 The ability showed by GW0742 to increase HDL and to reduce glucose in plasma might also play a role in preserving endothelial function in SLE mice.
Finally, a reduction in the number of endothelial progenitor cells and the deficiency in their function have been reported to occur in both human and murine SLE. 55 In particular, the capacity of endothelial progenitor cell for differentiation into mature endothelial cells is significantly impaired. 55 IL-10 has received attention as a genetic risk factor for SLE. Although IL-10 can play a protective role in atherosclerotic plaque formation in mice, in SLE, IL-10 serves as an intermediary of the deleterious effects of type 1 interferons to induce endothelial progenitor cell dysfunction. 56 The administration of GW0742 to SLE mice was able to reduce plasma level of IL-10, which might also contribute to improve endothelial function in SLE.
Because of the experimental design used, this study has several limitations, and some questions remain to be explored. First, which genes are activated or repressed to mediate the protective effects of the PPARβ/δ agonist in SLE? Second, does it occur primarily in immune cells or in the vascular endothelium, or is it a combination of both?
In conclusion, our study demonstrates that pharmacological PPARβ/δ activation in SLE mice improves endothelium-dependent relaxation, essentially by preserving the NO-mediated component and reduces SBP. This protective effect may be attributable to a decrease in the vascular oxidative stress by normalizing the expression of NADPH oxidase subunits, as a result of reduced plasma levels of autoantibodies and other plasmatic insults (hyperglycemia and proinflammatory cytokines) and direct anti-inflammatory and antioxidant tissue actions.
Perspectives
SLE treatments have improved over the last decades, resulting in better control of organ damage associated to this disease. However, current therapies are not completely optimal because they can promote significant side effects, and the premature cardiovascular complications frequently develop in this patient population. Therefore, the search of new strategies that prevent or improve endothelial dysfunction and decrease metabolic abnormalities associated with premature vascular damage in SLE is considered as an important priority in the health care for these patients. Our findings identify PPARβ/δ as a promising target for an alternative approach in the treatment of SLE. 
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